Loading
companiesCompany
Caribou Biosciences
CRISPR-edited allogeneic CAR-T company whose vispa-cel (CB-010) matched autologous CAR-T efficacy in lymphoma in 2025 data.
Overview
Vispacabtagene regedleucel (CD19, chRDNA-edited) holds RMAT, Orphan, and Fast Track designations for B-NHL; ANTLER phase 1 data (November 2025) showed efficacy and durability on par with autologous products and outpatient-compatible safety; enrolling ~20 more second-line LBCL patients to confirm an HLA-matching strategy; IND cleared in lupus.
Similar pages
- CompanyFate Therapeutics
Shares Allogeneic cell banks: one donor, hundreds of doses, Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19.
- CompanyCentury Therapeutics
Shares Allogeneic cell banks: one donor, hundreds of doses, Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy.
- CompanyImugene
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- CompanyCellogen Therapeutics
Shares Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- PersonWaseem Qasim
Shares CRISPR functional genomics, Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy.
- CompanyPoseida Therapeutics
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- PersonPolina Stepensky
Shares Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
- Key paperUCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL
Shares Allogeneic donor and iPSC master cell banks, Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CD19.